Diabetic macular edema (DME) is a condition where fluid builds up in the eye, making it hard to see. It's often linked to diabetic retinopathy (DR), a major cause of blindness for working adults. The eyes can get better if this fluid is controlled quickly. There's a protein called vascular endothelial growth factor (VEGF) that can make blood vessels grow and leak, worsening DME. To help, doctors use anti-VEGF medicines that stop this growth. Some medicines like Ranibizumab and Aflibercept have been effective, but not for everyone. The study aims to see if having dyslipidemia (an imbalance of fats in the blood like cholesterol) affects how well these treatments work for people with DME.

• This study is for type II diabetes patients with specific eye issues.
• It does not include those with certain eye conditions or past eye treatments.
• Participation involves receiving anti-VEGF injections to observe the response.